Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Eli Lilly ( NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight ...

Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% ...

Elon Musk validated the use of GLP-1 drugs in a post on X on Wednesday. But Robert F. Kennedy Jr. has said he's opposed to Americans using them to fight obesity.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... "These new head-to-head clinical trial results underscore that tirzepatide, with a 6.5 ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our ...

Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.

After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...